Glucagon-like peptide 1 receptor agonists, more commonly known as GLP-1 medications, have dominated headlines for their ...

Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...

While Ozempic is rising in popularity, experts say the drug is not designed or approved for weight loss. (Oct. 3, 2024) ...

The shortage of Eli Lilly’s (LLY) blockbuster diabetes and weight loss drugs is officially over, according to the U.S. Food ...

The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...

In real-world settings multiple factors contribute to non-persistence, including adverse effects, high cost-sharing and ...

Research shows patients taking weight-loss drugs like Ozempic and Wegovy are more likely to have food left in the stomach or ...

Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filing in the gaps.

Among 140 patients who underwent colonoscopy or a colonoscopy-plus-EGD, "inadequate bowel preparation" (stool retained in the ...

Improvements in the Dermatology Life Quality Index score and hidradenitis suppurativa flares were seen in people who achieved ...

Some oncologists are turning to GLP-1 agents to help patients shed excess pounds, with the goal of improving cancer outcomes.

The quest for effective and safe weight loss solutions has long been a focus of medical research. In recent years, a novel ...